Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTOR-BC: Ribociclib in advanced breast cancer
NCT05452213Phase 4Recruiting
- Sponsor
- Institut Frauengesundheit
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ribociclib in breast cancer, sponsored by Institut Frauengesundheit. Started Oct 2022; status: recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05452213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05452213.